ARTICLE | Clinical News
Daxas roflumilast: Additional Phase III data
November 16, 2009 8:00 AM UTC
Additional data from the double-blind, international Phase III HELIOS trial in 743 patients showed that once-daily 500 ug oral Daxas plus Spiriva tiotropium for 24 weeks significantly improved breath...